LONDON (dpa-AFX) - GlaxoSmithKline (GSK.L, GSK) and Theravance Inc. (THRX) announced that the licence application for the use of fluticasone furoate, or FF, and vilanterol or VI, in patients with chronic obstructive pulmonary disease has been withdrawn from the current Japanese New Drug Application. GlaxoSmithKline believes that the data from the 6-month studies alone may be insufficient to support the efficacy of the combination and its components.
The application for FF/VI as a potential treatment for asthma remains under review in Japan.
Copyright RTT News/dpa-AFX
Kostenloser Wertpapierhandel auf Smartbroker.de